Comparison between Wako-WB003 and Fungitec G tests for detection of (1→3)-β-D-glucan in systemic mycosis

Hossain, Mozammal; Miyazaki, Tatsuya; Mitsutake, Kotaro; Kakeya, Hiroshi; Yamamoto, Yoshihiro; Yanagihara, Katsunori; Kawamura, Sumio; Otsubo, Takakazu; Hirakata, Yoichi; Tashiro, Takayoshi; Kohno, Shigeru

doi:10.1002/(sici)1098-2825(1997)11:2<73::aid-jcla1>3.0.co;2-l

Cited by 48 publications

(34 citation statements)

References 16 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…False-positive tests have been reported in patients undergoing hemodialysis, patients with cirrhosis, recipients of antitumor polysaccharides, and patients immediately following abdominal surgery. An assay that utilized turbidometric readings for the detection of 1,3-␤-D-glucan, the Fungitec G test for the diagnosis of systemic mycoses, was shown to have lower sensitivity than the colorimetric assay (122). Aspergillus DNA detection by PCR assays.…”

Section: Diagnostic Laboratory Technologymentioning

confidence: 99%

AspergillusInfections in Transplant Recipients

2005

View full text Add to dashboard Cite

Aspergillus infections are occurring with an increasing frequency in transplant recipients. Notable changes in the epidemiologic characteristics of this infection have occurred; these include a change in risk factors and later onset of infection. Management of invasive aspergillosis continues to be challenging, and the mortality rate, despite the use of newer antifungal agents, remains unacceptably high. Performing molecular studies to discern new targets for antifungal activity, identifying signaling pathways that may be amenable to immunologic interventions, assessing combination regimens of antifungal agents or combining antifungal agents with modulation of the host defense mechanisms, and devising diagnostic assays that can rapidly and reliably diagnose infections represent areas for future investigations that may lead to further improvement in outcomes

show abstract

Section: Diagnostic Laboratory Technologymentioning

confidence: 99%

AspergillusInfections in Transplant Recipients

2005

View full text Add to dashboard Cite

show abstract

“…The other methods for BDG detection are pretreatment by dilution and heating with detection by an endpoint chromogenic assay and alkali pretreatment with kinetic or endpoint BDG determinations. Of the BDG assays in the marketplace, differences in sensitivity, specificity and measurement values among the commercial kits have been reported (Hossain et al 1997;Yoshida et al 2002;Moro et al 2003). These differences are believed to be related to variables including differences in pretreatment, detection methodology, cut-off value, standard β -glucans and species of horseshoe crab as a source of reagent.…”

Section: Discussionmentioning

confidence: 99%

Measurement of (1-3)-.BETA.-D-Glucan Derived from Different Gauze Types

Kanamori

Kanemitsu

Miyasaka

et al. 2009

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

“…In patients colonized with Candida spp., the BG levels were not higher than those in patients who were not colonized, confirming previous reports (10,19,21). Some reports suggest that bacterial bloodstream infections can cause elevated serum BG levels (22,23).…”

Section: Vol 49 2011 Beta-d-glucan In Immunocompromised Icu Patientmentioning

confidence: 99%

Beta- d -Glucan Detection as a Diagnostic Test for Invasive Aspergillosis in Immunocompromised Critically Ill Patients with Symptoms of Respiratory Infection: an Autopsy-Based Study

et al. 2011

View full text Add to dashboard Cite

Beta-(1,3)-D-glucan (BG) detection is an emerging tool to diagnose invasive fungal infections (IFIs). Invasive aspergillosis (IA) is the second most common IFI in immunocompromised intensive care unit (ICU) patients.We retrospectively analyzed the serum BG concentration (Fungitell; Associates of Cape Cod) in immunocompromised ICU patients with proven IA and in immunocompromised ICU patients in whom autopsy failed to show IFI. The study was performed in a 17-bed medical ICU in a 1,900-bed referral hospital. Patients at risk for IA were eligible for inclusion when at least two additional clinical signs were present. Patients with other IFIs were excluded. Fourteen patients with IA and 33 patients who had no IFI were eligible for inclusion. Serum BG levels were significantly higher in patients with IA than patients without an IFI (P < 0.01). Using a cutoff of 140 pg/ml, the sensitivity and specificity were 85.7 and 69.7%, respectively; the positive and negative predictive values were 54.5 and 92.0%, respectively. The positive and negative likelihood ratios were 2.83 and 0.21, respectively. Although serum BG concentrations were higher in immunocompromised ICU patients with IA than in patients with the same risk factors who did not have IFI on autopsy, the moderate performance characteristics of this test limit its use as a diagnostic test for IA in this population.The incidence of invasive fungal infections (IFIs) has markedly increased in recent decades. Despite development of new antifungal drugs, the mortality rate from IFIs remains high, particularly in intensive care unit (ICU) patients. Invasive aspergillosis (IA) is the second most common IFI in immunocompromised ICU patients. The prognosis of IA is poor; mortality rates up to 100% have been reported in mechanically ventilated chronic obstructive pulmonary disease patients with IA (2), and in nonneutropenic critically ill patients with IA, rates up to 89% were published (5). A retrospective study in our medical ICU showed an observed mortality rate of 80% in patients suffering from IA, compared to a predicted mortality rate of 48% (14).An important determinant of the prognosis is the time lag between the onset of infection and the administration of antifungal drugs (3,25). This phase can be long due to diagnostic difficulties. Classical methods such as culture and biopsy are invasive and time-consuming tools (9). Detection of fungal cell wall components is a rapid and attractive tool to diagnose IFIs. Beta-(1,3)-D-glucan (BG) is one of those components and is present in a wide variety of pathogenic fungi such as Candida spp., Fusarium spp., Aspergillus spp., and Pneumocystis spp. The cell wall of Zygomycetes does not contain BG; Cryptococcus spp. have a capsule that captures BG before it is released into the bloodstream (12). BG is also present in the fungal wall of Penicillium spp. and Paecilomyces spp., which can cause contamination of the sample.Aspergillus spp. have galactomannan (GM) as another important cell wall component. GM is released into the blood...

show abstract

Comparison between Wako-WB003 and Fungitec G tests for detection of (1→3)-β-D-glucan in systemic mycosis

Cited by 48 publications

References 16 publications

AspergillusInfections in Transplant Recipients

AspergillusInfections in Transplant Recipients

Measurement of (1-3)-.BETA.-D-Glucan Derived from Different Gauze Types

Beta- d -Glucan Detection as a Diagnostic Test for Invasive Aspergillosis in Immunocompromised Critically Ill Patients with Symptoms of Respiratory Infection: an Autopsy-Based Study

Contact Info

Product

Resources

About